Molnupiravir as an Early Treatment for COVID-19: A Real Life Study.

Michela PontolilloClaudio UcciferriPaola Borrelli Marta Di NicolaJacopo VecchietFalasca Katia

Published in: Pathogens (Basel, Switzerland) (2022)

Participants treated with molnupiravir, albeit in risk categories, demonstrated early clinical improvement, no need for hospitalization, and a low rate of adverse events.

Keyphrases

coronavirus disease
sars cov
replacement therapy